talphera receives extension to meet nasdaq listing requirements

Published 05/06/2025, 22:28
talphera receives extension to meet nasdaq listing requirements

Today, Talphera, Inc. (NASDAQ:TLPH) announced it has been granted an additional 180-day period by Nasdaq to comply with the $1.00 minimum bid price requirement, according to a filing with the Securities and Exchange Commission. The San Mateo, California-based pharmaceutical company must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days by December 1, 2025. Currently trading at $0.49, the stock has declined over 50% in the past year, according to InvestingPro data, which shows the company’s market capitalization now stands at approximately $10 million.

Previously, on December 6, 2024, Nasdaq notified Talphera that its stock had closed below $1.00 for 30 consecutive business days, failing to meet the Nasdaq Global Select Market’s listing standards. Initially, the company was given until June 4, 2025, to regain compliance.

Talphera has since transferred its listing to the Nasdaq Capital Market, which allows for a second 180-day grace period under specific criteria. The company’s common stock continues to trade under the symbol "TLPH."

The firm is actively monitoring its stock price and considering measures, including a potential reverse stock split, to address the deficiency. Failure to meet the requirement by the deadline could result in delisting, though Talphera would have the option to appeal to the Nasdaq Hearings Panel.

This update is based on a statement from Talphera’s SEC filing.

In other recent news, Talphera Inc. reported a significant reduction in its cash operating expenses for the first quarter of 2025, bringing them down to $2.9 million from $4.2 million in the same period last year. The company also highlighted its ongoing nephro CRRT trial, which has received FDA-approved changes to the study design, aiming to streamline and expedite the trial process. Talphera’s financing strategy, structured in three tranches, has already seen the first tranche received, with further funding contingent on specific patient enrollment milestones. The company’s cash balance as of March 31, 2025, stood at $5.4 million, with a pro forma cash balance of $9.8 million after the recent financing. CEO Vince Angotti emphasized the company’s strategic focus on addressing unmet medical needs in CRRT. Additionally, Talphera plans to activate more clinical trial sites to enhance patient enrollment for its nephro CRRT trial. The company has also reduced its expected cash operating expense guidance for 2025 to between $17 million and $19 million. These developments reflect Talphera’s commitment to operational efficiency and strategic growth in the coming years.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.